the aid library

LIST OPTIONS

Filter

2248

Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update

Fuchs A., J. Bielickia, S. Mathur, et.al. World Health Organization (2016) C_WHO

Sepsis remains a leading cause of mortality and morbidity, especially during the first five days of life and in low and middle-income countries (LMIC) [1]. Hospital infection also remains a major cause of mortality in children despite progress encountered in the last decades.

External Link

Antimicrobial resistance in South East Asia: time to ask the right questions

Kakkar M., Chatterjee P. et. al. (2018) C2

Antimicrobial resistance (AMR) has emerged as a major public health concern, around which the international leadership has come together to form strategic partnerships and action plans. The main driving force behind the emergence of AMR is selection pressure created due to consumption of antibiotics... more

Download (601)

View PDF (637)

Kenya National Oral Health Policy 2022-2030

World Health Organisation (WHO) (2022) C_WHO

Oral health is defined as the absence of disease and a status that ensures optimal functioning of the mouth and its tissues in a manner preserving the highest level of function and self-esteem. Oral health enables an individual to eat, speak and socialise having no active disease, discomfort or disc... more

External Link

Clinical decisions and stigmatizing attitudes towards mental health problems in primary care physicians from Latin American countries

A. O. Rojas Vistorte , W. Ribeiro, C. Ziebold, et al. (2018) CC

The aim of this paper is to investigate how doctors working in primary health care in Latin American address patients with common mental disorders and to investigate how stigma can affect their clinical decisions PLoSONE 13(11):e0206440.https://doi.org/10.1371/journal.pone.0206440

Download (2278)

View PDF (2171)

Cancer
recommended

Hellen Gelband,Jha Prabhat, Rengaswamy Sankaranarayanan et al. The World Bank (2015) C1

This volume presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The Disease Control Priorities Volume 3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alte... more

Download (441)

View PDF (648)

Human and dog rabies prevention and control

World Health Organization World Health Organization WHO; Bill & Melinda Gates Foundation (2009) C_WHO

Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,... more

Download (97)

View PDF (83)

Guidelines for using the APCA African Children’s Palliative Outcome Scale

African Palliative Care Association APCA (2012) C2

In the absence of a such a measure, and building on the success of developing the APCA African Palliative Outcome Scale (POS) for adults, the African Palliative Care Association has developed the APCA African Children’s POS. The tool has been validated across diseases, countries, settings and ... more

Download (355)

View PDF (376)

WHO training package on environmental cleaning: Evaluation methodology guide

World Health Organization WHO (2024) C_WHO

This purpose of this guide is to inform robust evaluations of the WHO training package – a package aimed at personnel whose primary role in health-care facilities is environmental cleaning, hereafter referred to as cleaners. The WHO training package – Environmental cleaning and infection prev... more

Download (536)

View PDF (582)

Laboratory testing for the monkeypox virus
recommended

World Health Organization (WHO) (2022) C_WHO

Any individual that meets the suspected case definition of monkeypox should be offered testing in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Confirmation of monkeypox virus infection is based on nucleic acid amplification testing (NAAT), usi... more

Download (380)

View PDF (581)

Tuberculosis in the WHO African Region: 2023 progress update - September 2023

World Health Organisation (WHO) (2023) C_WHO

This brief update on tuberculosis (TB) in the African region covers the state of TB in the WHO African region, strategic priorities and targets and the impact of COVID-19 on essential services. This is followed by key figures for the region, the role of WHO in country support and, recognizing the im... more

Download (400)

View PDF (385)

COVID-19 natural immunity

World Health Organization WHO (2021) C_WHO

10 May 2021 This scientific brief replaces the WHO Scientific Brief entitled “’Immunity passports’ in the context of COVID-19”, published 24 April 2020. This update is focused on what is currently understood about SARS-CoV-2 immunity from natural infection. More information about considera... more

Download (599)

View PDF (788)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

WHEELCHAIR SERVICE TRAINING PACKAGE Reference Manual for Participants (Intermediate level)

Sarah Frost, Kylie Mines, Jamie Noon, Elsje Scheffler, and Rebecca Jackson Stoeckle WHO; USAID (2013) C_WHO

Following the release of the Wheelchair Service Training Package – Basic level (WSTP-B), WHO in partnership with United States Agency for International Development (USAID) has developed the Wheelchair Service Training Package – Intermediate Level (WSTP-I). WSTP-I is the second part of the WHO w... more

Download (426)

View PDF (381)

Social Stigma associated with COVID-19
recommended

World Health Organization (WHO); UNICEF; IFRC (2020) C_WHO

A guide to preventing and addressing social stigma. Social stigma in the context of health is the negative association between a person or group of people who share certain characteristics and a specific disease. In an outbreak, this may mean people are labelled, stereotyped, discriminated against,... more

External Link

The Health Literacy Toolkit For Low- and Middle-Income Countries

Sarity Dodson, Suvajee Good and Richard Osborne World Health Organization - Regional Office South-East Asia (2015)

A series of information sheets to help empower communities and strengthen health systems This series of information sheets introduces health literacy, its relevance to public policy, and the ways it can be used to inform the promotion of good health, the prevention and management of communicab... more

External Link

Financing HIV Programming: How Much Should Low And Middle-Income Countries and their Donors Pay?

Galarraga, O.; V. J. Wirtz; Y. Santa-Ana-Tellez et al. PLOS One (2013) C1

Global HIV control funding falls short of need. To maximize health outcomes, it is critical that national governments sustain reasonable commitments, and that international donor assistance be distributed according to country needs and funding gaps. We develop a country classification framework in t... more

Download (309)

View PDF (268)

COVID-19 in Yemen: preparedness measures in a fragile state

Dureab, F.; S. Al-Awlaqi and A.Jahn The Lancet (2020) CC

The Lancet DOI: 10.1016/S2468-2667(20)30101-8 WHO declared COVID-19 to be a pandemic on March 11, 2020. The pandemic eventually reached Yemen, with the first laboratory confirmed case announced on April 10. emen has structural vulnerabilities that have developed over a protracted period of conflic... more

Download (409)

View PDF (840)

2023 حالة أطفال العالم لعام

UN Children's Fund UNICEF (2024) CC

The article focuses on "The State of the World’s Children 2023" report published by UNICEF. It highlights the critical role of vaccines in saving lives and the challenges in global immunization efforts, especially for marginalized and underserved children. The report emphasizes the impact of COVID... more

Download (504)

View PDF (551)

Key political commitment documents for tuberculosis prevention and care and their intended influence in the WHO European Region

World Health Organization WHO, Regional Office for Europe (2019) C_WHO

This analytical report reviews and discusses the potential role and influence of political commitment in implementing endorsements and conducting policy in the field of tuberculosis (TB) prevention and care. It promotes discussion by comparing and analysing the extent to which selected international... more

Cancer recommended

Laboratory testing for the monkeypox virus recommended

Social Stigma associated with COVID-19 recommended

Cancer
recommended

Laboratory testing for the monkeypox virus
recommended

Social Stigma associated with COVID-19
recommended